Search Within

Howard Scher

Formats
  1. Journal Article (624)
  2. Meeting Abstract (463)
  3. Book Section (13)
  4. Conference Paper (11)
  5. Editorial (6)
  6. Review (6)
  7. Guidelines (3)
  8. Correspondence (2)
  9. Research Letter (2)
Groups
  1. Department of Medicine (1130)
  2. Genitourinary Oncology Service (1130)
  3. Solid Tumor Oncology Division (1130)
  4. GSK Faculty (305)
  5. Sloan Kettering Institute Faculty (249)
  6. Molecular Pharmacology and Chemistry Program Faculty (229)

More Groups

People
  1. Michael Morris (217)
  2. Susan Slovin (140)
  3. Dana Rathkopf (133)
  4. Daniel Danila (111)
  5. Steven Larson (110)
  6. Victor Reuter (97)

More People

Years
  1. 2025 (8)
  2. 2024 (12)
  3. 2023 (15)
  4. 2022 (25)
  5. 2021 (19)
  6. 2020 (35)

More Years

Publications
  1. Journal of Clinical Oncology (328)
  2. Clinical Cancer Research (85)
  3. Cancer Research (54)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (47)
  5. Journal of Urology (36)
  6. European Urology (35)

More Publications

Publishers
  1. American Society of Clinical Oncology (335)
  2. American Association for Cancer Research (197)
  3. Elsevier Science, Inc. (119)
  4. Elsevier Inc. (72)
  5. Nature Publishing Group (58)
  6. Oxford University Press (47)

More Publishers

Results (1130)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Zelefsky, M. J.; Spratt, D. E.; Kollmeier, M.; Slovin, S. F.; Aghalar, J.; Hearn, J. W.; Den, R. B.; Deville, C.; Borofsky, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E)
    Meeting Abstract

    Armstrong, A. J.; Halabi, S.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Healy, P.; Anand, M.; Rothwell, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP plus D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)
    Meeting Abstract

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Vaishampayan, U. N.; Shevrin, D. H.; Harrison, M. R.; Tagawa, S. T.; Milowsky, M. I.; Graff, J. N.; Beer, T. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Microsatellite instability in prostate cancer and response to immune checkpoint blockade
    Meeting Abstract

    Abida, W.; Cheng, M. L.; Armenia, J.; Middha, S.; Autio, K. A.; Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Carbone, E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials
    Meeting Abstract

    Pond, G. R.; Sonpavde, G.; Fizazi, K.; De Bono, J. S.; Basch, E. M.; Scher, H. I.; Smith, M. R.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Estimation of tumor-derived mutant allele fractions in cfDNA by shallow whole genome sequencing and fragment size analysis
    Meeting Abstract

    Yang, J.; Marass, F.; Ulz, P.; Shady, M.; Cheng, M. L.; Kothari, P.; Gedvilaite, E.; Somnay, S.; Shukla, N.; Modak, S.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Oncologic therapy for solid tumors alters the risk of clonal hematopoiesis
    Meeting Abstract

    Bolton, K.; Ptashkin, R.; Braunstein, L.; Kelly, D.; Devlin, S. M.; Coombs, C. C.; Moarii, M.; Patel, M.; Bernard, E.; Berthon, A.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
    Meeting Abstract

    Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I.; Shapiro, J. D.; McDermott, R.; Hussain, A.; Patnaik, A.; Petrylak, D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Hulling, M.; Carbone, E.; Dittamore, R.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems
    Meeting Abstract

    Hornberger, J.; Graf, R. P.; Hulling, M.; Attard, G.; Allan, A.; Dittamore, R.; Scher, H. I.
    Annals of Oncology (2018)

    Fulltext@MSK | Save